US Stock Market Move | CEO stated that they will continue to provide the Wegovy combination drug, resulting in Hims & Hers Health (HIMS.US) increasing by over 6%.
As of the deadline for submission, the stock rose more than 6%, reaching $44.17 per share.
On Thursday, the stock price of Hims & Hers Health (HIMS.US) rose, and as of the time of writing, the stock rose by more than 6%, reaching $44.17. In terms of news, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) recently ended its partnership with Hims & Hers Health to distribute the weight loss therapy Wegovy (semaglutide). However, Hims & Hers CEO Andrew Dudum stated that their telemedicine platform will still offer affordable Wegovy compounded medication.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
